Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.61 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476822 | 1.00 | OXTR (0.61) | OXTRAVPR1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13083574 | 1.00 | OXTR (0.61) | OXTRAVPR1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5476815 | 1.00 | OXTR (0.61) | OXTRAVPR1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5482929 | 0.90 | OXTR (0.64) | OXTRAVPR1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5482924 | 0.90 | OXTR (0.64) | OXTRAVPR1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5570187 | 0.89 | AVPR1A (0.69) | OXTRAVPR1ASPHK1FFAR2SLC6A7 | |
| SCHEMBL5570185 | 0.89 | AVPR1A (0.69) | OXTRAVPR1ASPHK1FFAR2SLC6A7 | |
| SCHEMBL5473608 | 0.89 | AVPR1A (0.69) | OXTRAVPR1ASPHK1FFAR2SLC6A7 | |
| SCHEMBL5482133 | 0.89 | OXTR (0.68) | OXTRAVPR1AMEN1KMT2APOLB | |
| SCHEMBL5041532 | 0.89 | OXTR (0.68) | OXTRAVPR1AMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725526-B1 | METHOD FOR PREPARING PYRROLIDINE OXIMES | SERONO LAB (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | PPOX, PGF, OXTR | OXTR 3/4885AVPR1A 398/4885SMN1; SMN2 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.